Roche Holding AG

2 416,00 

This 2026 equity research report examines Roche Holding AG at a critical turning point in global healthcare. After years of stagnation, Roche has regained momentum following its patent cliff. The company now benefits from a strengthened pharmaceutical pipeline and a resilient diagnostics business.

Description

This 2026 equity research report examines Roche Holding AG at a critical turning point in global healthcare. After years of stagnation, Roche has regained momentum following its patent cliff. The company now benefits from a strengthened pharmaceutical pipeline and a resilient diagnostics business.

The report explains why Roche stands as an overweight defensive investment with a 12‑month price target of 370 CHF. It also reviews the company’s financial recovery, including CHF 60.5 billion in 2024 sales and expanding operating margins.

Key areas covered in this report include:

  • Investment thesis and valuation outlook
  • Pharmaceutical and diagnostics divisional performance
  • Pipeline catalysts across oncology and metabolic disease
  • SWOT analysis and competitive risks
  • DCF and relative multiple valuation modeling

In addition, the analysis compares Roche against global biopharma peers. It highlights both long‑term opportunities and structural risks. As a result, investors gain a clear, balanced view of Roche’s future value.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Only logged in customers who have purchased this product may leave a review.

Related products